Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · June 10, 2024

Osimertinib After Chemoradiotherapy for Stage III EGFR-Mutated NSCLC

The New England Journal of Medicine

 

Additional Info

The New England Journal of Medicine
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
N. Engl. J. Med 2024 Jun 02;[EPub Ahead of Print], S Lu, T Kato, X Dong, MJ Ahn, LV Quang, N Soparattanapaisarn, T Inoue, CL Wang, M Huang, JC Yang, M Cobo, M Özgüroğlu, I Casarini, DV Khiem, V Sriuranpong, E Cronemberger, T Takahashi, Y Runglodvatana, M Chen, X Huang, E Grainger, D Ghiorghiu, T van der Gronde, SS Ramalingam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading